logo
Plus   Neg
Share
Email

Software AG Q1 Profit Down; Backs FY21, Mid-term View - Quick Facts

Software AG (STWRY.PK) reported Friday that its first-quarter non-IFRS net income was 17.0 million euros or 0.23 euro per share, compared to last year's 27.9 million euros or 0.38 euro.

EBIT in the first quarter was 15.3 million euros, down 34 percent year-on-year, and operating profit or EBITA, non-IFRS was 24.5 million euros, down 38 percent.

EBITA magrin, non-IFRS, was 13.4 percent , down from 19.2 percent last year.

Group revenue fell 12 percent to 183.1 million euros from prior year's 207 million euros. For the first quarter, product revenue was 146.5 million euros, down 4 percent lower than last year.

Recurring revenue grew 6 percent and was 89 percent of total product revenue. Subscription and SaaS recurring revenues grew 77 percent and 42 percent respectively.

During the first quarter, Software AG's overall bookings of 88.8 million euros represented 4 percent growth and were driven by continued strong progress in Digital Business.

Looking ahead, the company reiterated 2021 guidance. EBITA margin, non-IFRS, is expected to be 16 percent to 18 percent.

Further, the company confirmed mid-term ambitions of 1 billion euros Group revenue, 25 percent to 30 percent operating margin, 85 percent to 90 percent recurring product revenue and roughly 15 percent Digital Business CAGR in 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer L Brands, Inc. announced Tuesday that its Board of Directors has unanimously approved a plan to separate the company into two independent publicly traded companies. The two public companies will be Bath & Body Works, one of the world's leading bath, body and home fragrance retailers, and Victoria's Secret, including Victoria's Secret Lingerie, PINK and Victoria's Secret Beauty. Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage temperature conditions, the U.S. Food and Drug Administration said. The Food and Drug Administration on Monday expanded the emergency use authorization of Pfizer-BioNTech's Covid-19 vaccine to include 12- to 15-year-olds. "The FDA's expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age...
RELATED NEWS
Follow RTT